Free Trial
NASDAQ:TIL

Instil Bio (TIL) Stock Price, News & Analysis

Instil Bio logo
$14.61 -2.02 (-12.15%)
Closing price 04/4/2025 04:00 PM Eastern
Extended Trading
$14.52 -0.08 (-0.58%)
As of 04/4/2025 07:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Instil Bio Stock (NASDAQ:TIL)

Key Stats

Today's Range
$14.34
$16.32
50-Day Range
$14.61
$26.31
52-Week Range
$9.62
$92.00
Volume
140,313 shs
Average Volume
117,431 shs
Market Capitalization
$95.34 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$114.00
Consensus Rating
Buy

Company Overview

Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer. It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.

Remove Ads

Instil Bio Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
39th Percentile Overall Score

TIL MarketRank™: 

Instil Bio scored higher than 39% of companies evaluated by MarketBeat, and ranked 595th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Instil Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Instil Bio has only been the subject of 4 research reports in the past 90 days.

  • Read more about Instil Bio's stock forecast and price target.
  • Earnings Growth

    Earnings for Instil Bio are expected to grow in the coming year, from ($13.32) to ($11.47) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Instil Bio is -1.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Instil Bio is -1.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Instil Bio has a P/B Ratio of 0.42. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Instil Bio's valuation and earnings.
  • Percentage of Shares Shorted

    16.48% of the float of Instil Bio has been sold short.
  • Short Interest Ratio / Days to Cover

    Instil Bio has a short interest ratio ("days to cover") of 6.
  • Change versus previous month

    Short interest in Instil Bio has recently increased by 3.69%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Instil Bio does not currently pay a dividend.

  • Dividend Growth

    Instil Bio does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    16.48% of the float of Instil Bio has been sold short.
  • Short Interest Ratio / Days to Cover

    Instil Bio has a short interest ratio ("days to cover") of 6.
  • Change versus previous month

    Short interest in Instil Bio has recently increased by 3.69%, indicating that investor sentiment is decreasing.
  • Search Interest

    Only 3 people have searched for TIL on MarketBeat in the last 30 days. This is a decrease of -63% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Instil Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Instil Bio insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    46.50% of the stock of Instil Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    60.56% of the stock of Instil Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Instil Bio's insider trading history.
Receive TIL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Instil Bio and its competitors with MarketBeat's FREE daily newsletter.

TIL Stock News Headlines

Instil Bio reports Q4 adjusted EPS ($1.08) vs. ($1.26) last year
Trump to redistribute trillions of dollars
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
Instil Bio: Time To Hop On The Summit Wave?
JMP Securities Keeps Their Hold Rating on Instil Bio (TIL)
See More Headlines

TIL Stock Analysis - Frequently Asked Questions

Instil Bio's stock was trading at $19.09 at the beginning of 2025. Since then, TIL stock has decreased by 23.5% and is now trading at $14.61.
View the best growth stocks for 2025 here
.

Instil Bio, Inc. (NASDAQ:TIL) posted its quarterly earnings results on Tuesday, March, 4th. The company reported ($1.82) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($3.75) by $1.93.

Shares of Instil Bio reverse split on the morning of Friday, December 8th 2023. The 1-20 reverse split was announced on Friday, December 8th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, December 8th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Instil Bio (TIL) raised $250 million in an initial public offering on Friday, March 19th 2021. The company issued 13,900,000 shares at $17.00-$19.00 per share. Morgan Stanley, Jefferies, Cowen and Truist Securities acted as the underwriters for the IPO.

Shares of TIL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Instil Bio investors own include Tesla (TSLA), CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Taysha Gene Therapies (TSHA), Viking Therapeutics (VKTX), Golden Minerals (AUMN) and Walt Disney (DIS).

Company Calendar

Last Earnings
3/04/2025
Today
4/04/2025
Next Earnings (Estimated)
5/09/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:TIL
Fax
N/A
Employees
410
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$114.00
High Stock Price Target
$180.00
Low Stock Price Target
$52.00
Potential Upside/Downside
+680.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-156,090,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$34.72 per share
Price / Book
0.42

Miscellaneous

Free Float
3,491,000
Market Cap
$95.34 million
Optionable
No Data
Beta
1.73

Social Links

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

This page (NASDAQ:TIL) was last updated on 4/5/2025 by MarketBeat.com Staff
From Our Partners